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Abstract 
Introduction: The paper deals with the problem of wound healing, which is considered to 
remain one of the most pressing challenges of the modern medicine, despite a large variety of 
wound healing preparations. This results from a high level of domestic and military 
traumatism of the population, and the fact that many registered medications do not meet the 
requirements for modern wound healing preparations.  
Objectives:  To develop gel containing chitosan, taurine, allantoin, and to experimentally 
investigate its wound healing properties in pre-clinical studies on laboratory animals. 
Methods: The methodological approach was based on a range of theoretical, 
pharmacological, toxicological, histological, statistical, physico-chemical, biopharmaceutical, 
rheological methods, which ensured the development of an optimal, safe and effective wound 
healing preparation in the gel dosage form. 
Results: The developed chitosan gel containing taurine and allantoin meets the major modern 
requirements for wound and burn care. Physico-chemical compatibility of the chitosan gel 
components with taurine and allantoin were proved in the experimental studies. When applied 
either singly or repeatedly on the skin, the developed gel is reported to be of low toxicity; i n 
case of linear wounds, it demonstrates wound-healing properties, ensuring the increase of 
wound-disruption strength 1.5 times more in comparison with the control; in case of planar 
full-thickness skin wounds, it provides earlier complete healing (4 days earlier than in the 
control) and full epithelium recovery in the area of a wound defect. The given gel possesses 
burn-treating properties exceeding the efficiency of the "Solcoseryl" gel and reducing the 
half-healing period by 28%. When applied topically, the chitosan gel containing taurine and 
allantoin reveals anti-inflammatory and capillary-protective properties of moderate degree. 
Conclusion: It is possible to use 1.0% chitosan gel with 4.0% taurine and 0.5% allantoin to 
accelerate healing and provide epithelization without cosmetic defects of conditionally 
aseptic wounds and thermal skin burns up to IIIa degree to 1% of the body surface area; the 
gel should be applied 1-3 times a day locally, 0.5 g directly to the wound surface. 
Key words: wound healing; gel; preclinical studies; wound healing gel; chitosan; taurine; 
allantoin. 
Introduction 
The treatment and care of wounds of various 
etiology are stated to remain an acute issue of 
current medicine, since the level of military, 
domestic, sports and industrial traumatism is 
increasing, and annually one in ten inhabitants of 
Russia receives injuries of various severity [1, 2]. 
Currently over 1000 pharmaceuticals are registered 
as preparations for topical wound healing on the 
territory of the Russian Federation; however, not 
Rus. 
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all of them meet the requirements for adequate 
wound healing preparations [3, 4]. 
Use of combined topical preparations 
revealing synergism of active agents and bases in 
various dosage forms – aerosols, ointments, pastes, 
gels, liniments and solutions – is considered to be 
more preferable. According to the recent scientific 
research data gels are reported to be the 
preparation of choice for wound and burn care, 
since they have a number of advantages in 
comparison with other dosage forms, i.e., they do 
not disrupt fluid balance and gas exchange; their 
pH ranges from 4.0 to 6.0, which is close to that of 
the skin surface; they are easily applied and 
smoothly spread over the skin surface; they are 
able to bind exudates and prevent reverse 
migration of microorganisms into a wound; they 
have cooling effect as a result of  water 
evaporation; they contribute to  processes of 
granulation and epithelization; they are able to 
successfully release active agents out of the base, 
provide deep penetration in tissues, increase 
prolonged effect of active agents and are effective 
for 18-24 hours [5, 6]. Natural biopolymers such as 
chitosan extracted from crustacean shells are of 
special attention among the great variety of gel 
bases, since they maintain humid conditions and 
gas exchange in a wound. Besides, they provide the 
development of the acidic environment 
contributing to reparative processes, and have an 
antibacterial and antioxidant effect [7, 8, 9]. The 
choice of components was performed on the basis 
of the data obtained experimentally in certain 
preclinical studies. Taurine (2-aminoethanesulfonic 
acid) was stated to be a promising agent for wound 
healing as the substance having an anti-oxidant, 
anti-inflammatory, angioprotective, membrane-
stabilizing, osmoregulatory effect. Its topical 
application increased the wound-disruption 
strength, and reduced malondialdehyde and 
histamine level in the wound tissue [10, 11]. 
Allantoin was also considered to be one of the 
highest potential agents; this component is noted to 
be a low molecular heterocyclic compound having 
a wound healing effect due to stimulation of 
fibroblast proliferation and synthesis of 
extracellular matrix; this leads to the formation of 
a negligible scar [12, 13, 14, 15, 16]. 
Thus, the development of a balanced and 
effective wound healing preparation for the 
external use in the form of gel containing chitosan, 
taurine and allantoin is considered to be a currently 
important line of research nowadays; this gel 
should exceed existing analogues and meets the 
majority of modern requirements towards wound 
healing preparations that eventually allows 
extending the range of these products on the 
Russian pharmaceutical market. 
All the above mentioned helps define the aim 
of this research study: to develop gel containing 
chitosan, taurine, allantoin and experimentally 
investigate its wound healing properties in pre-
clinical species. 
Materials and methods 
The study was conducted in accordance with 
The Guidelines on Pre-Clinical Trials of 
Pharmaceuticals, Part I (Mironov A.N., 2012). It 
was performed on the basis of the Pharmaceutical 
Faculty of the Federal State-Funded Educational 
Institution of Higher Education “Voronezh State 
University”. Male and female conventional, 
sexually mature, white outbred mice, rats and 
Guinea pigs were included in the study. The 
methodological approach was based on a range of 
theoretical, pharmacological, toxicological, 
histological, statistical, physico-chemical, 
biopharmaceutical, rheological methods, which 
ensured the development of an optimal, safe and 
effective wound healing preparation in the gel 
dosage form. 
The research design followed the rules and 
regulations of the Ethical Principles and Guidelines 
for Experiments on Animals, was conducted in 
accordance with the requirements of the European 
Convention for the Protection of Vertebrate Animals 
used for Experimental and other Scientific Purposes 
(Guidelines for accommodation and care of animals); 
it fully reflects the thesis structure (Fig. 1).
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Fig. 1. The research design 
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381 pre-clinical species were included in the 
study: 160 3-month-old conventional, sexually mature, 
white outbred mice (females and males) weighed 18-
25 g; 176 3-month-old conventional, sexually mature, 
white outbred rats (females and males) weighed 180-
220 g and 5-month-old conventional, sexually mature, 
white outbred rats (females and males) weighed 280-
300 g; 45 2-month-old white color Guinea pigs 
(females and males) weighed 350-400 g. The animals 
were taken from the vivarium of the Federal State 
Budget Educational Institution of Higher Education 
“Voronezh N.N.Burdenko State Medical University”. 
The animals were kept in the vivarium of the Federal 
State-Funded Educational Institution of Higher 
Education “Voronezh State University” in accordance 
with the sanitary rules and standards; they received 
full-value granulated meal (AO “Voronezh 
Experimental Feed Plant”, Russia) with free access to 
water; the cleaning of cages was carried out daily. 
The plan and the study protocol were approved 
by the Ethical Committee on the Expertise of 
Biomedical Research of the Federal State-Funded 
Educational Institution of Higher Education 
“Voronezh State University” (Protocol No. 42-02, 
adopted on 05.10.2015). The study was performed in 
accordance with the requirements of the European 
Convention for the Protection of Vertebrate Animals 
used for Experimental and other Scientific Purposes 
(1986); the Principles of Good Laboratory Practice 
GOST R-53434-2009; and the Order of the Ministry 
of Health and Social Development of the Russian 
Federation, August 23, 2010, No. 708n “About the 
approval of laboratory practice rules”. 
The target of research was the chitosan gel with 
taurine and allantoin (ChTA) developed under 
supervision of Doctor of Pharmacy, Professor Slivkin 
A. I. at the Department of Pharmaceutical Chemistry 
and Pharmaceutical Technology of the Pharmaceutical 
Faculty of the Federal State-Funded Educational 
Institution of Higher Education “Voronezh State 
University” [17]. 
The composition of the gel is developed on the 
basis of pharmacological and technological data 
obtained during the study. The substances used in the 
study are as follows: Chitosan (2-amino-2-deoxy-
(1→4)-β-D-glucan) of high viscosity, extracted from 
crab shells, produced in Sigma-Aldrich, Japan, the 
United States Pharmacopeia (USP 34 NF 29), with 
weight-average molecular weight equal 600 kDa and 
the degree of deacetylation equal 85%; Taurine (2-
aminoethanesulfonic acid) 99%, ZAO "Vekton", 
Russia, Pharmacopeian Monograph.2.1.0039.15; 
Allantoin (5- ureidohydantoin) 98%, Acros Organics, 
Belgium, the United States Pharmacopeia (USP 34 
NF29). 
The development of the chitosan gel containing 
taurine and allantoin was based on physico-chemical, 
pharmacological, rheological and biopharmaceutical 
investigations. 
Cutaneous acute toxicity was investigated under the 
application use of the gel in male and female mice (n=40, 
21,1±2, 3 g) in accordance with The Guidelines on Pre-
Clinical Trials of Pharmaceuticals, Part I (Mironov A.N., 
2012); the gel was applied eight times during 24 hours 
with one-hour break between applications. The study of 
cutaneous sub-chronic toxicity was conducted in 
accordance with the requirements of “the Guidelines for 
the Testing of Chemicals. Repeated Dose Dermal 
Toxicity: 21/28-day Study", GOST 32642-2014 (2015). 
Cutaneous sub-chronic toxicity was studied under the 
application use of the gel in male and female rats (n=20, 
206, 8±12.1 g). Local irritative effect of the ChTA gel was 
investigated using the technique of cutaneous applications 
in male and female white color Guinea pigs (n=20, 
363,7±13,9 g) divided into two groups, 10 species in each 
group. The conjunctival provocation test was performed in 
male rats (n=25, 288, 4±6.8 g) and male and female white 
color Guinea pigs (n=25, 355, 4±19, 7). The tube test was 
used to evaluate the ChTA gel absorption through skin in 
male rats (n=20, 215, 7±8.9 g). 
The impact of the ChTA gel and each of its 
components and reference preparations – the 
“Solcoseryl” gel and the “Levomekol” ointment – on 
the healing dynamics were studied on the model of 
planar full-thickness skin wounds in male mice (n=84, 
of 20.0±1.5 g). 
Investigations on the model of linear wounds were 
performed in male rats (n=21, 203, 4±12.0 g). 
Euthanasia was conducted on the 8th day by overdosing 
of ether anesthesia; 2×3 cm flap was incised from the 
wound surface; a tensiometer was used to measure the 
wound-disruption strength [18]. 
Anti-burn effect was studied on the model of 
thermal skin burn in male rats (n=42, 276, 0±17.6 g). 
Experimental burn wounds were simulated using an 
electrical device for the contact thermal burn. The metal 
plate of the device, sized 2.5×2.5 cm, heated to 200 ºC 
was applied to the skin for 10 seconds; this resulted in 
the third-degree burn as big as 600±50 mm2. 
Trypan blue exclusion test at the site of 
inflammation was used to evaluate a capillary protective 
effect of the gel in male mice (n=36, of 18.8±2.0 g). 
Formalin test was used to investigate topical anti-
inflammatory effect in male rats (n=48, 280, 0 ± 20.0 g) 
(a swollen rat leg). 
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Pathological, hematological and biochemical 
investigations were carried out according to 
conventional methods (Malakhova M. Y., 1995; 
Kishkun A. A., 2007 Suleymanov S. M., 2012). 
Statistical significance of findings obtained in the intact, 
control and experimental groups was assessed by 
Student’s t-test in case of parametric distribution, and 
Wilcoxon-Mann-Whitney test in case of non-parametric 
distribution.  
Results 
When developing pharmaceuticals with complex 
compositions a special attention is paid to the study of 
physico-chemical compatibility. Compatibility of the 
components of the chitosan gel with taurine and 
allantoin was assessed and analyzed by the method of 
infrared spectroscopy. The obtained infrared specters of 
taurine, allantoin and chitosan substances are given in 
Figure 2. 
Fig. 2. Infrared specters of taurine, allantoin, chitosan and their mixture 
The analysis of infrared specters of the chitosan, 
taurine and allantoin mixture has proved that specific 
absorption bands responding to sulfonic stretching 
vibrations in the molecules of taurine, amides stretching 
vibrations in the molecule of allantoin, amines 
stretching vibrations in the molecule of chitosan are 
retained. Moreover, there have not been revealed new 
absorption bands in the mixture; this fact indicates the 
lack of covalent binding of allantoin and taurine 
molecules with chitosan macro-molecules.  The data 
obtained support the absence of physico-chemical 
interrelations between the gel components and give an 
opportunity to combine them when developing a 
pharmaceutical preparation. 
Concentration of the gel-forming agent was 
chosen under the visual inspection of the created 
model samples with concentrations of 0.5%, 1.0%, 
2.0%, 3.0%; the following indicators were taken into 
account: swelling property, transparency, 
homogeneity, spreading capacity of the gel. Optimal 
concentration of the chitosan gel-forming agent equal 
1.0% was used in further studies. Rheological 
investigations of the ChTA gel model samples were 
conducted to study the shear stress at temperatures 
20ºC and 37ºC. It has been established that the 
structural viscosity of the ChTA gel slightly 
decreased at the temperature 37 ºC , however, it 
remained within the range of the rheological 
optimum for the gels (from 2 to 10 Pa·s). Ascending 
and descending curves of hysteretic loops shown in 
Figure 3 indicate that the studied СhTA gel has the 
thixotropic properties; this fact predicts its optimal 
flow property during mixing, which is necessary to 
facilitate packaging of the preparation due to its 
ability to be easily squeezed out of a tube and 
conveniently applied on the skin. Biopharmaceutical 
investigations support the fact that the active agents 
of the given composition of the gel are equally 
released during 24 hours (Figure 4).
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Fig. 3. Rheograms of the gel flows Fig. 4. Dynamics of  taurine and allantoin release 
The following composition of the gel has been 
developed on the basis of the data obtained in the 
study of the compatibility of the components, 
rheological characteristics, in the biopharmaceutical, 
screening and pharmacological investigations:  
Chitosan 1.0 g 
Taurine 4.0 g 
Allantoin  0.5 g. 
Acetic acid 0.5 g. 
Purified water   up to 100 g. 
Quality standards of the chitosan gel with 
taurine and allantoin have been defined taking into 
account the following parameters: description, 
identification, assay, pH, microbial purity, container 
fill and viscosity. The shelf-life of the chitosan gel 
with taurine and allantoin has been stated to be 18 
months at the temperature 2- 8˚C. 
When investigating the acute toxicity of the 
ChTA gel LD50 was calculated on the Berens 
formula; the Gaddam formula was used to assess the 
value of standard error. When applying the ChTA gel 
on the skin LD50 constituted 719.58±99.10 g/kg; this 
exceeded an assumed therapeutic dose equal 0.2 – 0.5 
g/kg in 3600 times and proved the  high level of safety 
and low risk of overdosing. Therefore, the chitosan gel 
with taurine and allantoin is stated to be low toxic and 
may be included in the IV substance hazard category – 
low-hazardous substances (Berezovskaya I.V., 2003; 
GOST 12.1.007-76). 
No skin-resorptive, locally irritative or 
organotropic effects have been registered when 
applied the ChTA gel daily for 28 days, dosed 7.2 
g/kg that corresponds to 1/100 of LD50. Histological 
investigations proved that no alterations were 
observed in the structural organization of the liver, 
kidneys and skin of white rats after repeated 
application of the ChTA gel during 28 days in 
comparison with the control group. 
Application of the ChTA gel on the conjunctiva 
of Guinea pigs and rats was accompanied with short-
term slight redness disappearing in 5 minutes; no 
irritative effect was observed in 15 minutes or 24 
hours. This slightly expressed irritative effect likely 
resulted from the occurrence of 0.5% acetic acid. In 
general the ChTA gel does not have irritative effect 
on the conjunctiva. 
The comparative evaluation of the influence of 
the chitosan gel with taurine and allantoin on the 
dynamics of the healing process performed on the 
planar full thickness wounds in mice proved that 
animals favourably tolerated application of the 
chitosan gel with taurine and allantoin; the gel did not 
result in the irritative effect, hyperemia or swelling of 
the skin surfaces; it did not influence the level of 
general moving activity of pre-clinical species. No 
fatal cases, wound abscess or complicated course of 
the wound process were registered during the period 
of observation; the gel was easily applied on the 
wounds, absorbed wound discharges, did not 
desiccate a wound bed and kept the humid 
environment in a wound. 
Gradual decrease of the wound area was 
observed at all stages of the wound process during 
the whole research period. In the third group the 
application of the “Levomekol” ointment reduced the 
wound area by 16.38% on the 9th day in comparison 
with the control (p<0,05). In the fourth group the use 
of the “Solcoseryl” gel  resulted in the reduction of 
the wound healing period by 2 days; the gel reliably 
had a positive impact on the reduction of the  wound 
area by 29,93% on the 7th day in comparison to the 
control (p<0,05). In the fifth group the wounds were 
treated with the 1.0% chitosan gel, which caused the 
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reduction of the wound healing period by 3 days; on 
the 6th and 8th day the wound area decreased by 
22.81% and 40.51% respectively in comparison to 
the control (p<0.05). In the sixth group the wound 
area reduced after the application of the 4.0% taurine 
solution on the wound surface by 21.07% and 
35.75% on the 5 and 8 day respectively in 
comparison with the control (p<0.05). In the seventh 
group the 0.5% allantoin solution was applied on the 
wound surface of animals; on the 7th day this 
resulted in the accelerated wound healing by 25.38% 
(p<0.05). In the eighth group, where the wounds were 
treated with the 1.0% taurine solution, there was 
noted the reduction of the wound area by 19.88% on 
the 8th day, by 20.27% on the 9
th
 day in comparison 
with the control (p<0.05). In the ninth group the 
wounds were irrigated with the 0.125% allantoin 
solution that led to the reduction of the wound area 
by 11.89% on the 7
th
 day in comparison with the 
control (p<0.05). In the tenth group the wounds were 
irrigated with the 0.25% taurine solution, in the 
eleventh group the 0.03% allantoin solution was 
applied; slight improvement of the wound healing by 
8.20% and 6.03% respectively were registered on the 
7
th
 day in comparison with the control. In the twelfth 
group the treatment of the wound surface with the 
developed ChTA gel contributed to the full wound 
recovery 4 days earlier in comparison with the 
control group; the wound-healing effect became 
apparent right at the end of the 1
st
 day and was 
characterized by the decrease of the wound area by 
5.62%, on the 7th day the wound area decreased by 
42.60%, on the 9th day the wound area decreased by 
56.62% in comparison with the control (p<0.05). The 
ChTA gel reduced the time of the wound healing by 
4 days when compared with the “Levomekol” 
ointment and decreased the wound area by 40.24% 
on the 9
th
 day (p<0.05); the treatment of the wound 
surface with the ChTA gel accelerated the process of 
wound healing by 25.38% on the 9
th
 day (p<0.05) 
when compared with the “Solcoseryl” gel; the data 
obtained are presented in Table 1. 
Half-healing periods were determined based on 
the dynamics of alteration of the wound area in the 
control and experimental animals. The data obtained 
are given in Figure 5. 
Application of the combined ChTA gel reduces 
the time of wound half-healing by 47.94% (p<0.05) 
when compared to untreated animals. Comparative 
analysis of the wound healing efficiency of the ChTA 
gel proves that it reduces the period of wound half-
healing in comparison with the chitosan gel by 
23.95%, in comparison with the “Solcoseryl” gel by 
17.35%, in comparison with the “Levomekol” 
ointment by 38.71% (p<0.05). 
Fig. 5. Half-healing period of planar experimental wounds.  
Note: * – P<0.05 – statistical significance in comparison with the control 
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Table 1 
Comparative evaluation of the wound-healing activity of the chitosan gel with taurine and allantoin and its components, 
“Solcoseryl” gel, “Levomekol” ointment on the model of planar full-thickness wound 
Day 
Area of planar full-thickness wound, mm
2
 
Control 
Levomekol 
Ointment 
Solcoseryl gel 
1.0% Chitosan 
gel 
ChTA gel 
Taurine solution 
4,0% 
Allantoin 
solution 0,5% 
Taurine 
solution 1,0% 
Allantoin 
solution 0,125% 
Taurine 
solution 0,25% 
Allantoin 
solution 0,031% 
0 0.65±0.03 0.62±0.03 0.66±0.04 0.63±0.05 0.61±0.04 0.63±0.06 0.64±0 0.63±0.05 0.63±0.04 0.64±0.06 0.62±0.05 
1 0.58±0.07 0.57±0.05 0.62±0.07 0.58±0.08 0.51±0.02**● 0.57±0.07 0.56±0.02 0.65±0.05++ 0.63±0.03+ 0.61±0.04 0.60±0.05 
2 0.58±0.07 0.58±0.04 0.61±0.07 0.56±0.08 0.48±0.03*++ ● 0.55±0.05 0.56±0.05 0.63±0.05++ 0.62±0.03++ 0.59±0.03 0.57±0.05 
3 0.56±0.07 0.54±0.06 0.53±0.08 0.48±0.03 ** 0.44±0.03*++ 0.49±0.07 0.50±0.06 0.62±0.03+ 0.59±0.05++ 0.57±0.00 0.56±0.05 
4 0.57±0.05 0.54±0.07 0.51±0.04 0.43±0.05 * 0.36±0.03*+● 0.46±0.04 * 0.45±0.04 * 0.56±0.05+ 0.55±0.05+ 0.54±0.03 0.53±0.03 
5 0.56±0.05 0.54±0.07 0.47±0.05 * 0.36±0.04 * 0.30±0.03*+● 0.41±0.03 * 0.40±0.03 * 0.52±0.03+ 0.53±0.03+ 0.51±0.02** 0.53±0.03 
6 0.53±0.07 0.52±0.06 0.37±0.06 * 0.37±0.04 * 0.25±0.03*+● 0.35±0.03 * 0.33±0.04 * 0.49±0.05+ 0.47±0.03+ 0.47±0.03 ** 0.47±0.03 ** 
7 0.49±0.07 0.47±0.06 0.30±0.07 * 0.33±0.03 * 0.20±0.04*+● 0.33±0.02 * 0.32±0.05 * 0.42±0.03 **+ 0.40±0.02 *+ 0.43±0.04 0.43±0.04 
8 0.48±0.07 0.43±0.05 0.27±0.08 * 0.21±0.06 * 0.11±0.08 *++● 0.24±0.05 * 0.22±0.02 * 0.34±0.03 *+ 0.30±0.03 *+ 0.38±0.02 * 0.37±0.04 * 
9 0.40±0.06 0.28±0.08** 0.20±0.08 * 0.16±0.08 * 0.03±0.02 *++● 0.14±0.07 * 0.15±0.04 * 0.26±0.03 *+ 0.23±0.04 *+ 0.33±0.03 ** 0.30±0.04 * 
10 0.34±0.07 0.21±0.04 * 0.09±0.04 * 0.10±0.05 * 0.01±0.01 *+● 0.1±0.05 * 0.07±0.02 * 0.16±0.03 *++ 0.09±0.02 * 0.25±0.02 * 0.18±0.02 * 
11 0.26±0.04 0.17±0.04 * 0.06±0.06 * 0.02±0.01 * 0 0.07±0.05 * 0.02±0.02 * 0.09±0.03 * 0.02±0.01 * 0.19±0.03 * 0.08±0.01 * 
12 0.14±0.06 0.07±0.05 ** 0.02±0.01 * 0 0 0.05±0.04 * 0.01±0.01 * 0.04±0.02 * 0.02±0.01 * 0.08±0.01 ** 0.03±0.01 * 
13 0.09±0.07 0.03±0.04 0 0 0 0 0 0.01±0.01 0.01±0.01 0.02±0.01 0.01±0.01 
14 0.09±0.07 0.01±0.02 0 0 0 0 0 0 0 0 0 
Note: * – Р<0.05; ** – Р<0.01 – statistical significance in comparison with the control;+ – Р<0.05; ++ – Р<0.01 – statistical significance in comparison with the 1.0% chitosan gel ; ● 
– Р<0.05; ●● – Р<0.01 – statistical significance in comparison with the “ Solcoseryl” gel.
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At all stages of the wound process the maximal 
effect was notably manifested in the ChTA group, 
wherein, the small scar was formed on the 14
th
 day of 
the experiment. There were conducted morphometric 
investigations of planar full-thickness skin wounds 
(Table 2). 
Table 2 
Morphometric parameters of planar full-thickness wounds 
Group of animals 
Transverse size of epithelium, 
mm
2
 
Number of cellular elements of a skin scar, 
inc. × 400. 
Intact 66.98±4.48 - 
Control 21.83±2.68* 169.60±9.00 
Levomekol ointment 24.76±3.63*● 105.60±4.81● 
Solcoseryl gel 34.72±4.07*● 74.43±6.20● 
ChTA gel 42.58±3.69*● 40.10±5.08● 
1,0% chitosan gel 27.55±2.83*● 84.27±6.49● 
Taurine solution 4,0% 25.09±2.67*● 83.97±3.67● 
Allantoin solution 0,5% 24.59±3.11*● 86.03±5.51● 
Note: * – Р<0.05 – statistical significance in comparison with the intact group; ● – Р<0.05 – statistical significance in 
comparison with the control. 
In the group of animals where the wound surface 
was treated by the ChTA gel the epithelium of the 
wound defect area was completely recovered. 
Proliferation of the epithelium and the introduction of 
the basement membrane in the underlying tissue was 
revealed, fibrous connective tissue completely filling 
the volume of the wound defect was formed. Thick 
layer including hyalinized, collagen-rich connective 
tissue was formed under the epithelium. It should be 
noted that scar tissue loosening and decrease of 
vessels amount were observed with that (Figure 6C). 
Fig. 6A. A histological picture of the epidermis of the skin of 
the control group mice. 
Note: staining of hematoxylin-eosin. inc. × 200. Cells of all 
layers of the skin have multidirectional sizes and shapes, 
papillary dermis layer is smoothed 
Fig. 6B. A histological picture of the epidermis of the skin of 
mice after the action of the gel "Solcoseryl".  
Note: staining of hematoxylin-eosin. inc. × 200. There is no 
exudation and edema 
Fig. 6C. A histological picture of the epidermis of the skin  
of mice after exposure to the chitosan gel with taurine and 
allantoin.  
Note: staining of hematoxylin-eosin. inc. × 200. Fibroblasts 
and fibrocytes predominate over other types of cells, 
complete restoration of the epidermis is observed, collagen 
fibers have formed beams of various thicknesses and 
directions 
Thus, it has been established that on the model 
of the planar full-thickness wound the ChTA gel 
provides complete wound healing 4 days earlier than 
in the control group significantly exceeding the 
“Levomekol” ointment and the “Solcoseryl” gel by 
its efficiency; it ensures the reduction of the wound 
area by 40.24% and 25.38% respectively on the 9th 
day, provides complete epithelium restoration of the 
wound defect area due to reduction of proliferative 
inflammatory processes and complete scar 
involution. 
Comparative evaluation of the wound healing 
action of the chitosan gel with taurine and allantoin 
on the model of the linear wounds in rats 
demonstrated that the wound-disruption strength 
value constituted 68.36±2,04 g/mm2 on the 8th day 
after the injury in the control group. The results of 
wound-tensiometric investigations of linear wounds 
are shown in Figure 7. Application of the 
“Solcoseryl” gel on the 8th day significantly 
increased the wound-disruption strength by 14.6% in 
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comparison with the control (p<0.05) and constituted 
78.36±2.17 g/mm2. The ChTA gel provided increase 
of the wound-disruption strength by 50.4% as 
compared to the control (p<0.05) and constituted 
102.79±2.75 g/mm2. The ChTA gel in comparison 
with the “Solcoseryl» gel increased the strength of 
wound healing by 31.2% on the 8
th
 day (p<0.05). 
Fig. 7. Wound-tensiometric findings of the linear skin wound.  
Note: * – P<0.05 – statistical significance in comparison with the control; 
● – Р<0.05 – statistical significance in comparison with the reference preparation
On the 8
th
 day application of the ChTA gel resulted 
in the increased amount of lymphocytes by 3.14% 
(p<0.01), decreased amount of young, segmented, and 
stab neutrophils by 0.43%, 1.29%, and 1.86% 
respectively (p<0.05) in comparison with the control; 
with that, the shear index constituted 0.09 that indicated 
at the ChTA gel ability to reduce the severity of the 
inflammatory process. In general, during the experiment 
the level of total protein in blood serum in all groups 
was within the limits of species-specific norms for rats. 
On the background of the ChTA gel application on the 
3th and 8th day there was stated the reduced level of the 
substances of low and average molecular weight by 
38.8% and 37.0% respectively in comparison with the 
control (p<0.05) and by 28.9% and 12.2% in 
comparison with the “Solcoseryl” gel group (p<0.05); 
this supports the decrease of non-specific signs of 
inflammation and intoxication. 
Evaluation of the anti-burn effect of the chitosan 
gel with taurine and allantoin on the model of 
thermal skin burn allowed to conclude that the 
application of the ChTA gel in comparison with the 
“Solcoseryl” gel accelerated the process of burn 
wound healing by 13.85% and 25.42% on the 10th 
and 25th day respectively (p<0.05) and provided the 
complete burn wound healing 5 day earlier than in 
the control group (Table 3). 
Table 3 
Comparative evaluation of wound-healing activity of the chitosan gel with taurine and allantoin, 
the “Solcoseryl” gel on the model of a linear skin wound 
Day 
Burn wound area, mm
2
 
Control Solcoseryl ChTA 
0 562.29±29.19 569.00±27.18 580.14±15.93 
1 580.43±26.78 586.07±16.90 608.21±23.53 
5 595.93±32.35 593.93±17.53 536.29±14.82*● 
10 517.29±31.67 437.64±19.51* 365.86±32.12*● 
14 449.71±14.33 377.00±13.71* 295.57±34.20*● 
20 342.86±23.59 286.29±20.24* 179.00±26.86*● 
25 297.29±29.76 235.86±16.49* 93.00±22.57*● 
28 247.71±28.45 117.57±33.39* 34.43±4.65*● 
30 138.57±5.63 49.57±10.20 0 
35 3.71±4.24 0 0 
Note: * – Р<0.05 – reliability of the differences in comparison with the control; ● – Р<0.05 – reliability of the differences 
in comparison with comparison drug. 
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Application of the ChTA gel reduced the time of 
wound half-healing by 44.74% (p<0.05) in comparison 
with the control group that constituted 14.29±2.93 days. 
The comparative analysis of the wound-healing 
efficiency of the ChTA gel stated that the gel 
contributed to the reduction  of the half-healing period 
of burn wounds by 28.55% in comparison with the 
“Solcoseryl” gel. Treatment of burn wounds using the 
ChTA gel resulted in formation of a negligible post-
burn scar. Histological tests of the skin of white rats 
performed on the 28th day demonstrated that the gel 
application caused intensification of regenerative 
processes in the wound defect. In the epidermis the 
maturity of granular, thorny, and basal layers in the 
absence of inflammatory infiltrate was clearly 
recognized. In the dermis lympho-histiocytic infiltrate 
was absent.  In the granulation tissue the fibrous 
structures prevailed; this is considered to be the 
criterion of maturity (Figure 8C).  
Fig. 8A. Histological picture of the epidermis of the skin 
of the control group rats 
Note: staining of hematoxylin-eosin. inc. × 160.  
There is a network of "young" fibroblasts 
Fig. 8B. A histological picture of the skin epidermis of rats 
after the action of the gel "Solcoseryl".  
Note: staining of hematoxylin-eosin. Uv. × 160. In the 
field of view there are single blood-filled vessels  
of different calibers 
Fig. 8C. A histological picture of the epidermis of rat skin 
after exposure to chitosan gel with taurine and allantoin.  
Note: staining of hematoxylin-eosin. Uv. × 160. 
Recovered epidermal shaft developing from the edges of 
the wound defect fills the damaged skin area. 
Restored epidermal layer developing from the 
edges of the wound defect fills the damaged skin 
area. In the epidermis the maturity of granular, 
thorny, and basal layers in the absence of 
inflammatory infiltrate can be clearly recognized. 
In the dermis there is lack of lymphohistiocytic 
infiltrate. In the granulation tissue the fibrous structures 
prevail, that is considered to be the criterion of maturity. 
The ChTA gel application caused the decreased level of 
substances of low and average molecular weight by 
22.59% and 11.59% on the 14th and 28th day 
respectively in comparison with the control (p<0.05) 
and by 13.37% and 7.41% in comparison with the 
“Solcoseryl” gel group (p<0.05). Based on these data it 
can be assumed that the application of the ChTA gel 
contributes to decreased nonspecific signs of 
inflammation and post-burn intoxication. 
When investigating the anti-inflammatory action 
of the chitosan gel with taurine and allantoin using 
the formalin test (a swollen rat leg) there has been 
stated that preliminary application of the chitosan gel 
with taurine and allantoin significantly reduced 
swelling of the limb by 13.9% in 30 minutes, by 
16.6% in 180 minutes (p<0.05) (Figure 9). 
Thus, topical separate application of each 
component – taurine, chitosan, and allantoin – is 
reported to be less effective than combination of 
these substances in the gel dosage form. Preliminary 
application of the ChTA gel resulted in the reliable 
reduction of the limb swelling caused by the injection 
of formalin by 16.6% in 180 minutes (p<0.05); this 
proves the occurrence of the additive effect due to the 
combination of active substances formulated in the 
gel. Strength of the anti-inflammatory action of the 
ChTA gel is slightly lower than that of the “Voltaren 
Emulgel”, however, it is significantly higher than the 
anti-inflammatory action of the “Solcoseryl” gel and 
the “Levomekol” ointment. 
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Fig. 9. Comparative evaluation of the anti-inflammatory activity of the ChTA gel, “Voltaren Emulgel”, “Solcoseryl” gel, 
4.0% taurine solution, 0.5% allantoin solution, 1.0% chitosan gel on the model of formalin test (a swollen rat leg). 
Note: * – P<0.05; ** – Р<0.01 – statistical significance in comparison with the control 
Investigations of the capillary-protective action of 
the chitosan gel with taurine and allantoin in the trypan 
blue exclusion test at the site of inflammation 
demonstrated that application of the ChTA gel relevantly 
increased the time of appearance of staining by 40.0% 
and the time of distinct staining by 42.8% in comparison 
with the control (p<0.05) (Table 4). 
Table 4 
Impact of “Troxevasin” gel, ChTA gel, taurine and allantoin solution in the mono-composition 
on the reduction of vascular permeability in mice 
Group of animals 
Time of appearance of 
staining, sec. 
Difference with the 
control, % 
Time of distinct 
staining, sec. 
Difference with 
the control, % 
Control 81.17±0.75 - 122.33±1.03 - 
“Troxevasin” gel 117.83±2.32* 45.2 173.67±2.50* 42.0 
Gel HTA 113.67±0.82* 40.0 174.67±1.51* 42.8 
Taurine 4,0% in 
saline 
99.83±2.32* 23.0 162.00±3.58* 32.4 
Allantoin o,5% in 
saline 
86.00±1.67* 6.0 127.50±1.64* 4.2 
Gel chitosan 1,0% 83.17±1.94** 2.5 125.00±2.61** 2.2 
Note: * – P<0.05, ** – P<0.01 – statistical significance in comparison with the control. 
Thus, taurine, chitosan, and allantoin have 
slightly expressed capillary-protective action in 
mono-composition; whereas, using these substances 
in combination, formulated in the ChTA gel, more 
expressed action supporting the manifestation of 
additive effect is observed. Application of the ChTA 
gel provides reliable reduction of the capillary 
permeability in the trypan blue exclusion test by at 
least 40.0% (p<0.05) if compared to the control 
group. This effect is comparable with the 
“Troxevisin” gel effect. 
Discussion 
Data obtained from scientific literature state that 
chitosan formulated in many dosage forms 
accelerates wound healing, manifests wound-healing 
effect at the all stages of the wound process; with 
that, it has haemostatic and antibacterial effect. 
* 
* 
* 
* 
* 
* 
** 
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“Voltaren emulgel” gel 
“Solcoseryl” gel 
“Levomekol” ointment 
ChTA gel
4.0% taurine in the NS
0.5% allantoin in the NS
1.0% chitosan gel
Swelling of the limb, the difference with the original group,% 
180 minutes
30 minutes
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Leading mechanisms of the wound-healing action of 
chitosan are considered to be the ability to accelerate 
migration of neutrophils and macrophages, to 
particularly provide proliferation of fibroblasts and 
collagen synthesis, as well as to increase the level of 
granulation tissue in the wound area, to ensure 
granulation tissue formation, vascularization, 
fibroplasia, epithelization and wound contraction; 
this results in accelerated wound-healing without 
formation of a rough scar [19, 20, 21, 22]. 
Results obtained in this study conform to the 
data of scientific research studies that taurine and 
allantoin have wound-healing effect. Application of 
the preparations from the anti-oxidant group is 
known to contribute to reduced negative impact of 
free radicals on the wound process. Taurine as an 
antioxidant reduces the processes of free-radical 
oxidation and stabilizes the cytoplasmic membrane, 
increases cell vitality and proliferation, which, in 
turn, affects the inflammation and collageno-geneses 
and leads to acceleration of the wound-healing 
process  due to synergetic, antioxidant and anti-
apoptotic effects [23, 24]. Topical treatment of 
wounds by taurine is reported to result in the 
formation of connective fibers in the dermis, 
significantly increasing the wound-disruption 
strength and accelerating the process of 
epithelization, reduce the malondialdehyde and 
histamine level; this may result from the impact of 
taurine on inhibition of lipid peroxidation [10, 11]. 
Application of taurine for wound care in mice has 
been proved to cause the reliable increase of volume 
density of collagenic bundles, length and density of 
vessels and fibroblast number density in comparison 
with the control group [24]. Taurine has positive 
impact on the activity of phagocytosis and is 
recommended for use in the period of post-burn 
rehabilitation to increase immunoprotection [25]. 
As for allantoin, it accelerates the growth of 
connective tissue, bones, and cartilages, has an 
antioxidant and moderate anti-inflammatory effect 
[26], helps remove young keloid scars, is included as 
a compound in the sunburn protective creams. It has 
been histologically proved that allantoin provides 
restoration of the damaged skin; mechanisms of the 
allantoin wound healing action are considered to be 
regulation of inflammatory response by inhibiting 
immune cell chemotaxis in the wound area, 
prevention of reactive oxygen intermediate release, 
stimulation of fibroblast proliferation and matrix 
synthesis, ability to reduce the number of 
inflammatory cells, which leads to formation of more 
negligible scar similar to healthy skin [12, 15, 16].  
The results obtained on the evaluation of anti-
inflammatory action conform to the literature data of 
other researchers and support that taurine and chitosan 
have a slightly expressed anti-inflammatory effect. An 
anti-inflammatory effect of taurine is known to be 
related to neutralization of hypochlorous acid (HOCI), 
which is produced by neutrophils myeloperoxidase. 
Taurine reacts with HOCI with formation of taurine 
chloramines, the latter possessing an anti-inflammatory 
effect [27, 28, 29]. Taurine chloramine affects the 
activation of transcription nuclear factor-kappa B (NF-
kB) due to methionine oxidation in Ik-B-α; that is why, 
no heterodimer phosphorylation with Ik-B-kinase and 
its translocation to the nucleus are observed. As a result 
the production of FNO- α, NO synthesis in 
macrophages and peroxynitrite synthesis decrease [30]. 
Chitosan, in turn, inhibits the ciclooxygenase-2 (COG-
2) enzyme providing an anti-inflammatory action [22].
Conclusions 
1. Physical and chemical compatibility of the
components of the chitosan gel with taurine and 
allantoin has been proved in this study. Based on 
pharmacological, rheological, biopharmaceutical 
investigations optimal composition of the gel is 
determined as follows: chitosan – 1.0; taurine – 4.0; 
allantoin – 0.5; acetic acid – 0.5; purified water up to 
100 g. 
2. The chitosan gel with taurine and allantoin
applied singly or repeatedly on the skin is reported to 
be of low toxicity (IV category of toxicity), does not 
result in the irritative, skin-resorptive and 
organotropic toxic effect. 
3. The chitosan gel with taurine and allantoin
manifests wound-healing properties increasing the 
wound-disruption strength in 1.5 times in comparison 
with the control in the treatment of planar wounds; in 
the treatment of the full-thickness skin wounds it 
provides complete healing 4 days earlier than in the 
control group and complete restoration of epithelium 
in the area of wound defect exceeding the efficiency 
of the “Levomekol” ointment by at least 40% and the 
“Solcoseryl” gel by 25%. 
4. The chitosan gel with taurine and allantoin is
reported to have an anti-burn effect, since, when 
compared to the control group, it provides complete 
healing 5 days earlier, significant decrease of the 
burn area by 29% on the 10th day, decrease of  
laboratory signs of inflammation and post-burn 
intoxication, improvement of regenerative processes 
and formation of slightly expressed post-burn scar 
exceeding the efficiency of the “Solcoseryl” gel by 
28%, if taking into account the criterion of half-
healing period. 
5. The chitosan gel with taurine and allantoin is
stated to provide significant reduction of the 
capillaries permeability in the trypan blue exclusion 
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test by at least 40% in the comparison with the 
control group; this result is comparable with the 
“Troxevasin” gel impact and supports reliable 
reduction of the limb swelling caused by formalin by 
16.6% in 180 minutes. An anti-inflammatory effect 
of the chitosan gel with taurine and allantoin is less 
than that of the “Voltaren Emulgel”, however, it 
significantly exceeding the effect of the “Solcoseril” 
gel and the “Levomekol” ointment. 
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